Real-world clinical outcomes under intravenous and subcutaneous esketamine protocols for treatment-resistant depression: a multicenter, retrospective study
BackgroundEsketamine is a promising therapeutic option for treatment-resistant depression (TRD). Intravenous (IV) administration is the most extensively studied parenteral route. However, subcutaneous (SC) administration may offer simpler, more scalable delivery. Multicenter real-world evidence comparing IV and SC routes of administration remains limited.ObjectiveTo report clinical outcomes and…
Read original article on Frontiers in Psychiatry | New and Recent Articles →Related news
-
My Journey to Mindfulness
United States
-
20 Things 90 Years of Wisdom Encouraged Me to Stop Worrying About
United States
-
Remote supervised exercise- and physical activity-based rehabilitation for post-stroke depression, anxiety, and quality of life: a systematic review, evidence map, and exploratory quantitative synthesis
Switzerland
-
Resilience and clinical recovery in first-episode schizophrenia: a 10-year longitudinal study of clinically recovered, non-recovered, and healthy control participants
Switzerland
-
Context presentation and native conversation structure in large language model responses to escalating suicide risk: a controlled multimodel evaluation
Switzerland
-
Case Report: Electroencephalography-informed low-frequency repetitive transcranial magnetic stimulation targeting the supplementary motor area in severe functional movement disorder
Switzerland
-
Anxiety and depressive symptoms and health-related quality of life in girls with central precocious puberty versus isolated premature thelarche: a comparative cross-sectional study
Switzerland
-
Observed readmission timing and diagnostic profiles among high-risk adolescents and general child and adolescent inpatients: a 10-year cohort study
Switzerland